aXichem AB Net Assets
aXichem AB net assets. Based on the latest financial reports, aXichem AB (AXIC-A) has net assets worth Skr58.07 Million SEK (≈ $6.25 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr67.76 Million ≈ $7.29 Million USD) and total liabilities (Skr9.69 Million ≈ $1.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore AXIC-A net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr58.07 Million |
| % of Total Assets | 85.7% |
| Annual Growth Rate | 15.12% |
| 5-Year Change | 30.77% |
| 10-Year Change | 167.07% |
| Growth Volatility | 74.86 |
Net Assets of aXichem AB (2008–2024)
Net assets of aXichem AB from 2008 to 2024. This chart illustrates how aXichem AB's net assets have evolved over time, based on quarterly financial data. See AXIC-A net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for aXichem AB (2008–2024)
The table below shows the annual net assets of aXichem AB from 2008 to 2024. For live market cap and overall valuation, see aXichem AB stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr70.16 Million ≈ $7.55 Million |
+44.58% |
| 2023-12-31 | Skr48.53 Million ≈ $5.22 Million |
+20.33% |
| 2022-12-31 | Skr40.33 Million ≈ $4.34 Million |
-28.37% |
| 2021-12-31 | Skr56.30 Million ≈ $6.06 Million |
+4.94% |
| 2020-12-31 | Skr53.65 Million ≈ $5.77 Million |
-20.11% |
| 2019-12-31 | Skr67.15 Million ≈ $7.23 Million |
+130.79% |
| 2018-12-31 | Skr29.10 Million ≈ $3.13 Million |
-14.07% |
| 2017-12-31 | Skr33.86 Million ≈ $3.64 Million |
-18.07% |
| 2016-12-31 | Skr41.33 Million ≈ $4.45 Million |
+57.33% |
| 2015-12-31 | Skr26.27 Million ≈ $2.83 Million |
+38.75% |
| 2014-12-31 | Skr18.93 Million ≈ $2.04 Million |
-24.02% |
| 2013-12-31 | Skr24.92 Million ≈ $2.68 Million |
+211.00% |
| 2012-12-31 | Skr8.01 Million ≈ $862.30K |
-12.24% |
| 2011-12-31 | Skr9.13 Million ≈ $982.51K |
+178.76% |
| 2010-12-31 | Skr3.28 Million ≈ $352.46K |
-42.02% |
| 2009-12-31 | Skr5.65 Million ≈ $607.93K |
-23.34% |
| 2008-12-31 | Skr7.37 Million ≈ $792.98K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to aXichem AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1676465700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
aXichem AB Net Assets Breakdown (December 2024)
aXichem AB net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.82 Million | 16.86% |
| Other Comprehensive Income | Skr-130.32 Million | -185.82% |
| Other Components | Skr206.45 Million | 294.36% |
| Total Equity | Skr70.13 Million | 100.00% |
aXichem AB Competitors by Market Cap
The table below lists competitors of aXichem AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chuan Huat Resources Bhd
KLSE:7016
|
$11.65 Million |
|
Pure Resources Ltd
AU:PR1
|
$11.65 Million |
|
Schroder Oriental Income Fund
LSE:SOI
|
$11.65 Million |
|
InnoTherapy Inc
KQ:246960
|
$11.65 Million |
|
Kingfish Company Nv
OL:KING
|
$11.64 Million |
|
Netlinkz Ltd
AU:NET
|
$11.64 Million |
|
Active Biotech AB
ST:ACTI
|
$11.63 Million |
|
NPK Co.Ltd
KQ:048830
|
$11.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in aXichem AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 48,505,000 to 70,134,000, a change of 21,629,000 (44.6%).
- Net loss of 17,813,000 reduced equity.
- New share issuances of 38,646,000 increased equity.
- Other comprehensive income decreased equity by 20,820,000.
- Other factors increased equity by 21,616,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-17.81 Million | -25.4% |
| Share Issuances | Skr38.65 Million | +55.1% |
| Other Comprehensive Income | Skr-20.82 Million | -29.69% |
| Other Changes | Skr21.62 Million | +30.82% |
| Total Change | Skr- | 44.59% |
Book Value vs Market Value Analysis
This analysis compares aXichem AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.20x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.74x to 1.20x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | Skr2.47 | Skr1.83 | x |
| 2009-12-31 | Skr1.90 | Skr1.83 | x |
| 2010-12-31 | Skr1.10 | Skr1.83 | x |
| 2011-12-31 | Skr2.83 | Skr1.83 | x |
| 2012-12-31 | Skr2.31 | Skr1.83 | x |
| 2013-12-31 | Skr5.45 | Skr1.83 | x |
| 2014-12-31 | Skr2.76 | Skr1.83 | x |
| 2015-12-31 | Skr3.28 | Skr1.83 | x |
| 2016-12-31 | Skr4.32 | Skr1.83 | x |
| 2017-12-31 | Skr2.25 | Skr1.83 | x |
| 2018-12-31 | Skr1.94 | Skr1.83 | x |
| 2019-12-31 | Skr4.08 | Skr1.83 | x |
| 2020-12-31 | Skr3.24 | Skr1.83 | x |
| 2021-12-31 | Skr3.32 | Skr1.83 | x |
| 2022-12-31 | Skr2.35 | Skr1.83 | x |
| 2023-12-31 | Skr2.39 | Skr1.83 | x |
| 2024-12-31 | Skr1.52 | Skr1.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently aXichem AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -207.85%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.06x
- Recent ROE (-25.40%) is above the historical average (-30.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -14.23% | 0.00% | 0.00x | 2.15x | Skr-1.79 Million |
| 2009 | -30.35% | 0.00% | 0.00x | 2.35x | Skr-2.28 Million |
| 2010 | -72.48% | 0.00% | 0.00x | 4.50x | Skr-2.70 Million |
| 2011 | -25.82% | 0.00% | 0.00x | 2.47x | Skr-3.27 Million |
| 2012 | -43.47% | 0.00% | 0.00x | 2.17x | Skr-4.28 Million |
| 2013 | -14.67% | 0.00% | 0.00x | 1.57x | Skr-6.15 Million |
| 2014 | -29.72% | -1496.81% | 0.01x | 1.34x | Skr-7.52 Million |
| 2015 | -28.26% | 0.00% | 0.00x | 1.18x | Skr-10.05 Million |
| 2016 | -14.69% | 0.00% | 0.00x | 1.14x | Skr-10.21 Million |
| 2017 | -21.78% | 0.00% | 0.00x | 1.14x | Skr-10.76 Million |
| 2018 | -34.12% | -2885.76% | 0.01x | 1.32x | Skr-12.84 Million |
| 2019 | -18.53% | -3627.99% | 0.00x | 1.03x | Skr-19.16 Million |
| 2020 | -25.19% | -1101.47% | 0.02x | 1.04x | Skr-18.88 Million |
| 2021 | -26.81% | -346.01% | 0.07x | 1.04x | Skr-20.72 Million |
| 2022 | -42.82% | -344.72% | 0.08x | 1.52x | Skr-21.29 Million |
| 2023 | -42.90% | -1150.41% | 0.03x | 1.27x | Skr-25.66 Million |
| 2024 | -25.40% | -207.85% | 0.12x | 1.06x | Skr-24.83 Million |
Industry Comparison
This section compares aXichem AB's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $774,441,249
- Average return on equity (ROE) among peers: -47.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| aXichem AB (AXIC-A) | Skr58.07 Million | -14.23% | 0.17x | $11.64 Million |
| Svenska Aerogel Holding AB (publ) (AERO) | $43.40 Million | -92.78% | 0.71x | $2.22 Million |
| Arla Plast AB (ARPL) | $362.60 Million | 2.68% | 0.61x | $86.25 Million |
| HEXPOL AB (publ) (HPOL-B) | $6.23 Billion | 22.35% | 0.40x | $3.33 Billion |
| I-Tech (ITECH) | $111.41 Million | 7.56% | 0.18x | $82.63 Million |
| Nexam Chemical Holding AB (NEXAM) | $154.70 Million | -11.04% | 0.47x | $26.69 Million |
| Organoclick AB (ORGC) | $13.29 Million | -60.10% | 0.52x | $9.80 Million |
| Photocat AS (PCAT) | $7.51 Million | 3.99% | 1.46x | $1.87 Million |
| Polygiene AB (POLYG) | $40.84 Million | 22.45% | 0.24x | $9.43 Million |
| Triboron International AB (publ) (TRIBO-B) | $3.21 Million | -324.43% | 0.93x | $6.93 Million |
About aXichem AB
aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings a… Read more